BRAWM: bendamustine, rituximab and acalabrutinib for Waldenström’s macroglobulinemia

Neil Berinstein, MD, FRCPC, ABIM, Sunnybrook Research Institute, Toronto, Canada, discusses results from the interim analysis of the Phase II BRAWM trial (NCT04624906), which is investigating the combination of bendamustine, rituximab and acalabrutinib as a first-line treatment for Waldenström’s macroglobulinemia (WM). Dr Berinstein explains the hope that this regimen, a combination of two established frontline therapies, will be able to induce a deeper response in patients. Dr Berinstein then shares the interim results, including the improved rate of complete and very good partial response (CR; VGPR), and the achievement of measurable residual disease (MRD) negativity. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.